LUNDBECK-FOUNDATION
5.3.2024 16:31:25 CET | Business Wire | Press release
The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience. This year’s award recognizes the pioneering work of three leading neuroscientists – Professor Larry Abbott at Columbia University (USA), Professor Terrence Sejnowski at the Salk Institute (USA), and Professor Haim Sompolinsky at Harvard University (USA) and the Hebrew University (Israel).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305504553/en/
Credit: The Lundbeck Foundation
Theoretical and computational neuroscience permeates neuroscience today and is of increasingly growing importance. The winners of The Brain Prize 2024 have made pioneering contributions to these scientific areas by uncovering some of the principles that govern the brain’s structure, function, and the emergence of cognition and behaviour.
The Brain Prize 2024 worth DKK 10 million (€1.3 million) is awarded to:
Larry Abbott (USA), Terrence Sejnowski (USA), and Haim Sompolinsky (Israel/USA) for their Foundational work in Computational and Theoretical Neuroscience.
Chair of The Brain Prize Selection Committee, Professor Richard Morris, explains the reasoning behind this year’s award:
“It is inconceivable to imagine modern brain sciences without the concomitant development of computational and theoretical neuroscience. The three scientists have applied novel and sophisticated approaches from physics, mathematics, and statistics to study the brain. They have developed vital tools for the analysis of highly complex datasets acquired by modern day experimental neuroscientists.
The three prize winners have also proposed conceptual frameworks for understanding some of the brain’s most fundamental processes such as learning, memory, perception and how the brain generates maps of the external world. They have also provided crucial new insights into what may go awry in several devastating disorders of the nervous system, such as epilepsy, Alzheimer’s disease, and schizophrenia. In addition, their scientific achievements have paved the way for the development of brain-inspired artificial intelligence, one of the emerging and transformational technologies of our time.”
On behalf of the Lundbeck Foundation, CEO Lene Skole extends her warmest congratulations to each of the three Brain Prize recipients:
“Their pioneering research has created trailblazing knowledge and paved the way for other scientists to better understand critical brain functions, also in relation to diseases. It aligns fully with our purpose of bringing discoveries to lives. Each of their scientific endeavours began in the 70’s, and their determination, courage and persistence over decades should serve as inspiration for other scientists, and indeed be rewarded.”
FACTS
The human brain consists of approximately 100 billion neurons connected by trillions of synaptic connections. Every function the brain performs relies on the flow of information through these staggeringly complex networks of neurons. A fundamental goal of neuroscience is to understand how these networks are wired together, and how the patterns of neural activity within them give rise to cognition and behaviour. The sheer complexity of the brain means that understanding its language requires theoretical and computational approaches.
Theoretical and computational neuroscience uses mathematics, computer science, theoretical analysis, and abstractions of the brain to understand the principles that govern its structure, how it processes information, generates behaviour, and gives rise to cognitive abilities as perception, imagination, intelligence, the formation of knowledge, memory, problem-solving, decision-making, and the production of language. The field has laid the foundations for the development of AI - one of the most revolutionary developments in modern science.
MORE INFO
Find out more – see the information pack of The Brain Prize 2024 >>
About The Brain Prize
The Brain Prize is the world’s largest neuroscience research prize, and it is awarded each year by the Lundbeck Foundation. The Brain Prize recognises highly original and influential advances in any area of brain research, from basic neuroscience to applied clinical research. Recipients of The Brain Prize may be of any nationality and work in any country in the world. Since it was first awarded in 2011, The Brain Prize has been awarded to 47 scientists from 10 ten different countries. The Brain Prize recipients are presented with their award by His Royal Highness, King Frederik of Denmark, at a ceremony in the Danish capital, Copenhagen.
About the Lundbeck Foundation
The Lundbeck Foundation is an enterprise foundation encompassing a comprehensive range of commercial and philanthropic activities – all united by its strong purpose; Bringing Discoveries to Lives. The Foundation is the long-term and engaged owner of several international healthcare and medtech companies – Lundbeck, Falck, ALK, Ellab, and Ferrosan Medical Devices – and an active investor in business, science and people through its commercial investments in the financial markets; in biotech companies based on Danish research and through philanthropic grants to science talents and programmes in Danish universities. The Foundation’s philanthropic grants amount to more than DKK 500m annually primarily focusing on the brain – including the world’s largest personal prize awarded in neuroscience, The Brain Prize.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305504553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press release
This is the fourth quantum computer deployed by IQM to customers in Finland to boost research and education in a growing ecosystem. The system named Aalto Q20 quantum computer is online at Aalto University and will enable students and scientists a unique first-hand access to a world-class quantum computer. The university will use the quantum computer to perform scientific experiments on advanced level and to support national and European quantum research activities. IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum compute
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press release
Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissionsBespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resiliencePartnership aligns with the science-based climate commitments of both companies Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multi
NTT DATA Unveils NVIDIA-Powered Enterprise AI Factories to Support Secure AI Adoption and Help Clients Drive Measurable ROI11.3.2026 11:00:00 CET | Press release
NTT DATA drives success in healthcare, manufacturing and other sectors with NVIDIA-powered technologies NTT DATA AI solutions now integrate NVIDIA AI Enterprise software, including NVIDIA NeMo and NIM Microservices to create a full-stack, production-ready, GPU-accelerated agentic AI platform NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI. NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to en
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health11.3.2026 10:00:00 CET | Press release
£65m investment in new oral health manufacturing plant in Shanghai to support growth in the world’s largest gum health market Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 - including its fastest growing cities – reaching aspirational shoppers in-store and online Custom designed taste, foamier sensation and premium packaging to appeal to local consumers Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 09:00:00 CET | Press release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
